+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2028

  • ID: 4330800
  • Report
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Apeptico
  • Athersys
  • BioMarck Pharmaceuticals
  • Faron Pharmaceuticals
  • Techpool Bio-Pharma
  • United Therapeutics
  • MORE
‘Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of ARDS in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period:2017-2028

Acute Respiratory Distress Syndrome (ARDS) - Disease Understanding

Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality. It is not known by the researchers regarding who will develop ARDS. Several factors, such as obesity, low protein in the blood, consumption of alcohol, blood transfusion. Several physiological factors, such as blood acidemia, hypoalbuminemia, low respiratory compliance, and high lactate also increase the risk of developing ARDS.

ARDS is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue. Clinically, this establishes as hypoxemia, with bilateral opacities on chest radiography, associated with reduced lung compliance and increased venous admixture and physiological dead space. Morphologically, diffuse alveolar damage is observed in the acute phase of ARDS.

The ARDS Epidemiology report gives a thorough understanding of the ARDS by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

Acute Respiratory Distress Syndrome (ARDS) - Epidemiology

The ARDS epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL). This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM, Severity Specific Incident Population of Acute Respiratory Distress Syndrome in the 7MM and Incident Population of ARDS by Risk Factors in the 7MM] scenario of ARDS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2028.

As per this analysis, the total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM was found to be 815,490 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in the United States and among the European 5 countries, Germany had the highest incident population of ARDS followed by Italy.

On the other hand, Spain had the lowest incident population of ARDS. Another estimate of this analysis shows that in terms of severity-specific incidence, a similar trend is observed in all countries, with the majority of the cases witnessed for moderate ARDS, except France, where severe cases of ARDS accounted for maximum patient population. Furthermore, the highest number of incident cases were assessed for ARDS due to Pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS.

Report Scope
  • The report covers a detailed overview of ARDS explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan
  • The report assesses the disease risk and burden and highlights the unmet needs of ARDS
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by type-specific cases and severity specific cases of ARDS in the 7MM
Acute Respiratory Distress Syndrome (ARDS) Report Key Strengths
  • 10-Year Forecast of ARDS epidemiology
  • 7MM Coverage
  • Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM
  • Severity Specific Incident Population of Acute Respiratory Distress Syndrome in the 7MM
  • Incident Population of Acute Respiratory Distress Syndrome by Risk Factors in the 7 MM
Acute Respiratory Distress Syndrome (ARDS) Report Assessment
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Apeptico
  • Athersys
  • BioMarck Pharmaceuticals
  • Faron Pharmaceuticals
  • Techpool Bio-Pharma
  • United Therapeutics
  • MORE
1. Key Insights

2. Acute Respiratory Distress Syndrome (ARDS): Epidemiology Overview at a Glance
2.1. Total Epidemiology Distribution of ARDS in 2017
2.2. Total Epidemiology Distribution of ARDS in 2028

3. Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview
3.1. Introduction
3.1.1. Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
3.1.2. Development of Berlin Definition of ARDS
3.1.3. Problems with the AECC definition and subsequent Berlin definition of acute respiratory distress syndrome (ARDS)
3.2. Causes and Risk Factors
3.2.1. Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
3.3. Pathophysiology of Acute Respiratory Distress Syndrome (ARDS)
3.3.1. Inflammatory Processes in ARDS
3.3.2. The initial event of injury
3.3.3. Endothelial Damage
3.3.4. Specific Mediators of Inflammation and Lung Damage in ARDS
3.3.5. Altered Pulmonary Physiology in ARDS
3.3.6. Genetics
3.4. Stages of Acute Respiratory Distress Syndrome (ARDS)
3.5. Ventilator-Induced Lung Injury (VILI)
3.6. Major Determinants of VILI
3.6.1. Ventilator determinants of VILI
3.6.2. Patient determinants of VILI
3.7. Diagnosis of Acute Respiratory Distress Syndrome (ARDS)
3.7.1. Imaging techniques in ARDS
3.7.2. Imaging findings in ARDS
3.7.3. Differential Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Methodology

5. 7MM Epidemiology Analysis
5.1. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
5.2. Severity Specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM

6. United States Epidemiology
6.1. Assumptions and Rationale
6.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United States
6.3. Severity-Specific Incident Population of ARDS in the United States
6.4. Incident Population of ARDS by Risk Factors in the United States

7. EU5 Epidemiology
7.1. Germany Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Germany
7.1.3. Severity-Specific Incidence of ARDS in Germany
7.1.4. Incident Population of ARDS by Risk Factors in Germany
7.2. France Epidemiology
7.2.1. Assumptions and Rationale
7.2.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), in France
7.2.3. Severity-Specific Incidence of ARDS in France
7.2.4. Incident Population of ARDS by Risk Factors in France
7.3. Italy Epidemiology
7.3.1. Assumptions and Rationale
7.3.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Italy
7.3.3. Severity-Specific Incidence of ARDS in Italy
7.3.4. Incident Population of ARDS by Risk Factors in Italy
7.4. Spain Epidemiology
7.4.1. Assumptions and Rationale
7.4.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Spain
7.4.3. Severity-Specific Incidence of ARDS in Spain
7.4.4. Incident Population of ARDS by Risk Factors in Spain
7.5. United Kingdom Epidemiology
7.5.1. Assumptions and Rationale
7.5.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United Kingdom
7.5.3. Severity-Specific Incidence of ARDS in the United Kingdom
7.5.4. Incident Population of ARDS by Risk Factors in the United Kingdom

8. Japan Epidemiology
8.1. Assumptions and Rationale
8.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), ARDS in Japan
8.3. Severity-Specific Incidence of ARDS in Japan
8.4. Incident Population of ARDS by Risk Factors in Japan

9. Appendix
9.1. Report Methodology

10. Capabilities

11. Disclaimer

12. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Faron Pharmaceuticals
  • Athersys
  • BioMarck Pharmaceuticals
  • Apeptico
  • United Therapeutics
  • Techpool Bio-Pharma
Note: Product cover images may vary from those shown
Adroll
adroll